Patents by Inventor Stephen Claridge

Stephen Claridge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20230120413
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: May 13, 2022
    Publication date: April 20, 2023
    Inventors: Mehrnaz POURASHRAF, Guillaume JACQUEMOT, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • Substituted benzimidazoles, their preparation and their use as pharmaceuticals
    Patent number: 11365186
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: June 21, 2022
    Assignee: EPIGENETIX, INC.
    Inventors: Mehrnaz Pourashraf, Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20210107893
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: May 22, 2020
    Publication date: April 15, 2021
    Inventors: Mehrnaz POURASHRAF, Guillaume JACQUEMOT, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
    Patent number: 10836742
    Abstract: This application relates to N-substituted bicyclic lactams of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to the N-substituted bicyclic lactams of formula (I) and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: November 17, 2020
    Assignee: Neomed Institute
    Inventors: Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • SUBSTITUTED IMIDAZOPYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20200299291
    Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: October 29, 2019
    Publication date: September 24, 2020
    Inventors: Mehrnaz POURASHRAF, Marc-Andre BEAULIEU, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • SUBSTITUTED [1,2,4]TRIAZOLO[4,3-A]PYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20200299292
    Abstract: This application relates to substituted [1,2,4]triazolo[4,3-a]pyridines of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted [1,2,4]triazolo[4,3-a]pyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: November 19, 2019
    Publication date: September 24, 2020
    Inventors: Malken BAYRAKDARIAN, Stephen CLARIDGE, Andrew GRIFFIN
  • Substituted benzimidazoles, their preparation and their use as pharmaceuticals
    Patent number: 10703740
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: July 7, 2020
    Assignee: Neomed Institute
    Inventors: Mehrnaz Pourashraf, Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • N-SUBSTITUTED BICYCLIC LACTAMS, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20200024253
    Abstract: This application relates to N-substituted bicyclic lactams of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to the N-substituted bicyclic lactams of formula (I) and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: August 11, 2016
    Publication date: January 23, 2020
    Inventors: Guillaume JACQUEMOT, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
    Patent number: 10519151
    Abstract: This application relates to substituted [1,2,4]triazolo[4,3-a]pyridines of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted [1,2,4]triazolo[4,3-a]pyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 31, 2019
    Assignee: Neomed Institute
    Inventors: Malken Bayrakdarian, Stephen Claridge, Andrew Griffin
  • Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
    Patent number: 10501459
    Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines of Formula I and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: December 10, 2019
    Assignee: Neomed Institute
    Inventors: Mehrnaz Pourashraf, Marc-Andre Beaulieu, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • SUBSTITUTED [1,2,4]TRIAZOLO[4,3-A]PYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20190031657
    Abstract: This application relates to substituted [1,2,4]triazolo[4,3-a]pyridines of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted [1,2,4]triazolo[4,3-a]pyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: January 27, 2017
    Publication date: January 31, 2019
    Inventors: Malken BAYRAKDARIAN, Stephen CLARIDGE, Andrew GRIFFIN
  • SUBSTITUTED IMIDAZOPYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20180312504
    Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: October 20, 2016
    Publication date: November 1, 2018
    Inventors: Mehrnaz POURASHRAF, Marc-Andre BEAULIEU, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffery S. ALBERT, Andrew GRIFFIN
  • SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20180237417
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: August 12, 2016
    Publication date: August 23, 2018
    Inventors: Mehrnaz POURASHRAF, Guillaume JACQUEMOT, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • KINASE INHIBITORS AND USES THEREOF
    Publication number: 20080255155
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds, compositions and methods for the inhibition of kinase activity. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: October 18, 2007
    Publication date: October 16, 2008
    Inventors: Stephane Raeppel, Oscar Saavedra, Stephen Claridge, Arkadii Vaisburg, Frederic Gaudette, Ljubomir Isakovic, Robert Deziel
  • INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
    Publication number: 20080064718
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: March 22, 2007
    Publication date: March 13, 2008
    Inventors: Oscar Saavedra, Stephen Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Frederic Gaudette, Ljubomir Isakovic, Marie Granger, Jubrail Rahil, Michael Mannion, Robert Deziel
  • Inhibitors of protein tyrosine kinase activity
    Publication number: 20080004273
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: May 30, 2007
    Publication date: January 3, 2008
    Inventors: Stephane Raeppel, Stephen Claridge, Oscar Saavedra, Arkadii Vaisburg, Robert Deziel, Lijie Zhan, Michael Mannion, Frederic Gaudette, Nancy Zhou, Ljubomir Isakovic
  • Inhibitors of VEGF receptor and HGF receptor signaling
    Publication number: 20070004675
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Application
    Filed: May 19, 2006
    Publication date: January 4, 2007
    Inventors: Oscar Saavedra, Stephen Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Robert Deziel, Michael Mannion, Nancy Zhou, Frederic Gaudette, Ljubomir Isakovic, Amal Wahhab, Marie-Claude Granger, Naomy Bernstein
  • INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING
    Publication number: 20060287343
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Application
    Filed: May 19, 2006
    Publication date: December 21, 2006
    Inventors: Oscar Saavedra, Stephen Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Robert Deziel, Michael Mannion, Nancy Zhou, Ljubomir Isakovic
  • Inhibitors of VEGF receptor and HGF receptor signaling
    Publication number: 20060074056
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Application
    Filed: July 28, 2005
    Publication date: April 6, 2006
    Applicant: MethylGene, Inc.
    Inventors: Arkadii Vaisburg, Stephen Claridge, Franck Raeppel, Oscar Saavedra, Naomy Berstein, Marie-Claude Granger, Lijie Zhan, Amal Wahhab, David Llewellyn